Phase 1 Solutions, LLC can support sponsors who want to integrate generative AI into  their Phase 1–1b workflows by acting as a clinically grounded design and  implementation partner from the Clinical Scientist vantage point. Leveraging decades of  hands-on experience with FIH/SAD/MAD and Phase 1b studies plus formal training in  AI for pharma and generative AI innovation

 

Phase 1 Solutions can help sponsors  identify high-value, safety-aligned use cases (such as protocol and ICF drafting copilots,  eligibility and screening assistants, safety narrative generators, and PK/PD data-review  copilots), define requirements, and ensure these tools are embedded into existing study  processes without disrupting ICH-GCP, data integrity, or inspection readiness  expectations. Acting as an extension of the sponsor’s early-phase clinical science  function, Phase 1 Solutions can provide study design input, protocol and CSR  clinical-section authorship, data review and dose-escalation decision support, and  oversight of how Generative AI outputs are validated and documented across sponsor– CRO interfaces, so that any AI-enabled workflow remains clinically sound, auditable,  and fully traceable from protocol through CSR.